How is CGM displacing SMBG fingerstick testing as the standard of care for Type 2 insulin-using patients?
Continuous glucose monitoring providing interstitial glucose measurements every 1 to 5 minutes and retrospective glucose pattern reports has demonstrated clinically meaningful HbA1c reductions of 0.4 to 0.8 percentage points in randomised controlled trials of Type 2 diabetes patients on basal insulin therapy — a patient population far larger than the Type 1 diabetes CGM-adopting population that first drove market growth — from glucose pattern visibility that enables titration decisions above fingerstick point-in-time measurement that cannot identify nocturnal hypoglycaemia and postprandial glycaemic patterns driving HbA1c elevation. Reimbursement policy expansion for CGM in basal-insulin-using Type 2 patients by Medicare, Medicaid, and major commercial payers sustains commercial CGM sensor and transmitter adoption across the large and growing T2D patient population.

How do closed-loop automated insulin delivery systems improve glycaemic control above manual CGM and pump therapy?
Hybrid closed-loop AID systems — where a control algorithm continuously calculates and adjusts basal insulin delivery from a connected pump based on real-time CGM glucose readings, predicting future glucose trajectory from glucose rate-of-change and meal announcements — achieve time-in-range (70 to 180 mg/dL) metrics of 70 to 80 percent in real-world use studies, substantially above the 55 to 65 percent TIR achieved by best-practice manual CGM and multiple daily injection therapy. The sleep time-in-range improvement from closed-loop overnight basal regulation — where the algorithm adjusts insulin delivery continuously without patient action — is among the most impactful patient-reported quality of life benefits of AID, sustaining adoption among T1D patients and increasingly T2D insulin-using patients as AID system indications expand.

What is sustaining tubeless patch insulin pump adoption growth above tethered catheter pump systems?
Tubeless insulin pump systems — where the pump pod containing insulin reservoir and infusion cannula adheres directly to the body without tubing connection to a separate controller device — eliminate the external catheter tubing management, clothing and activity interference, and disconnection requirements of tethered pump systems. Omnipod Dash and Omnipod 5 (Insulet) have sustained strong commercial growth from tubeless design advantages in paediatric and active adult T1D patients, and Omnipod 5’s closed-loop AID algorithm integration enabling smartphone control of both CGM data and pump settings without a separate controller device is sustaining first-time pump adoption among MDI patients transitioning to pump therapy. The tubeless convenience factor sustaining above-tethered-pump adoption is a primary commercial differentiation sustaining Insulet’s market position.

How are smart insulin pens bridging the gap between MDI therapy and full pump adoption?
Smart insulin pens — conventional insulin pen injectors with integrated dose capture, timing, and bluetooth data transmission to smartphone applications — record every insulin dose event with timestamp and duration, enabling cloud-based injection history visualisation that provides insulin delivery data transparency comparable to pump download reports for MDI-managed patients. Smart pen connectivity combined with CGM data integration in unified diabetes management applications enables insulin-on-board tracking, recommended correction bolus calculation, and missed dose reminders that conventional uncommunicating pens cannot provide. The clinical value of smart pen-CGM data integration sustaining improved HbA1c and reduced hypoglycaemia in MDI-managed T2D populations is sustaining insulin manufacturer investment in connected smart pen product platforms.

How are AI-enabled diabetes management platforms creating a new market segment above device hardware revenue?
AI-enabled diabetes management software platforms integrating CGM glucose data streams, insulin delivery records, dietary intake logs, physical activity, sleep quality, and menstrual cycle data generate personalised predictive analytics including meal-specific glycaemic impact scoring, optimised pre-prandial insulin timing recommendations, and activity-related hypoglycaemia prediction that aggregate to clinically meaningful HbA1c and time-in-range improvements above isolated CGM or pump data review. SaaS subscription revenue from AI diabetes management platforms generating recurring monthly fees per patient sustains software revenue above the hardware replacement cycle of CGM sensors and pump infusion sets, creating a new recurring revenue stream that insulin and device manufacturers are investing to develop alongside hardware ecosystems.

Which diabetes care device segments are growing fastest?
CGM T2D basal insulin patient indication expansion sustaining above-T1D sensor and transmitter volume growth, AID closed-loop system adoption displacing manual pump and MDI therapy, tubeless patch pump convenience sustaining above-tethered adoption, and AI diabetes management platform subscription revenue above hardware replacement cycles are the four fastest-growing segments.